Your browser doesn't support javascript.
loading
Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS- CoV-2 vaccine candidates in the Syrian hamster model.
Mohandas, Sreelekshmy; Yadav, Pragya D; Shete-Aich, Anita; Abraham, Priya; Vadrevu, Krishna Mohan; Sapkal, Gajanan; Mote, Chandrashekhar; Nyayanit, Dimpal; Gupta, Nivedita; Srinivas, Vellimedu Kannappa; Kadam, Manoj; Kumar, Abhimanyu; Majumdar, Triparna; Jain, Rajlaxmi; Deshpande, Gururaj; Patil, Savita; Sarkale, Prasad; Patil, Deepak; Ella, Raches; Prasad, Sai D; Sharma, Sharda; Ella, Krishna M; Panda, Samiran; Bhargava, Balram.
Afiliación
  • Mohandas S; Indian Council of Medical Research-National Institute of Virology, Sus Road, Pashan, Pune, Maharashtra 411021, India.
  • Yadav PD; Indian Council of Medical Research-National Institute of Virology, Sus Road, Pashan, Pune, Maharashtra 411021, India.
  • Shete-Aich A; Indian Council of Medical Research-National Institute of Virology, Sus Road, Pashan, Pune, Maharashtra 411021, India.
  • Abraham P; Indian Council of Medical Research-National Institute of Virology, Sus Road, Pashan, Pune, Maharashtra 411021, India.
  • Vadrevu KM; Bharat Biotech International Limited, Genome Valley, Hyderabad, Telangana 500 078, India.
  • Sapkal G; Indian Council of Medical Research-National Institute of Virology, Sus Road, Pashan, Pune, Maharashtra 411021, India.
  • Mote C; Department of Veterinary Pathology, Krantisinh Nana Patil College of Veterinary Science, Shirwal, Maharashtra 412801, India.
  • Nyayanit D; Indian Council of Medical Research-National Institute of Virology, Sus Road, Pashan, Pune, Maharashtra 411021, India.
  • Gupta N; Indian Council of Medical Research,V. Ramalingaswami Bhawan, P.O. Box No. 4911, Ansari Nagar, New Delhi 110029, India.
  • Srinivas VK; Bharat Biotech International Limited, Genome Valley, Hyderabad, Telangana 500 078, India.
  • Kadam M; Indian Council of Medical Research-National Institute of Virology, Sus Road, Pashan, Pune, Maharashtra 411021, India.
  • Kumar A; Indian Council of Medical Research-National Institute of Virology, Sus Road, Pashan, Pune, Maharashtra 411021, India.
  • Majumdar T; Indian Council of Medical Research-National Institute of Virology, Sus Road, Pashan, Pune, Maharashtra 411021, India.
  • Jain R; Indian Council of Medical Research-National Institute of Virology, Sus Road, Pashan, Pune, Maharashtra 411021, India.
  • Deshpande G; Indian Council of Medical Research-National Institute of Virology, Sus Road, Pashan, Pune, Maharashtra 411021, India.
  • Patil S; Indian Council of Medical Research-National Institute of Virology, Sus Road, Pashan, Pune, Maharashtra 411021, India.
  • Sarkale P; Indian Council of Medical Research-National Institute of Virology, Sus Road, Pashan, Pune, Maharashtra 411021, India.
  • Patil D; Indian Council of Medical Research-National Institute of Virology, Sus Road, Pashan, Pune, Maharashtra 411021, India.
  • Ella R; Bharat Biotech International Limited, Genome Valley, Hyderabad, Telangana 500 078, India.
  • Prasad SD; Bharat Biotech International Limited, Genome Valley, Hyderabad, Telangana 500 078, India.
  • Sharma S; Indian Council of Medical Research-National Institute of Virology, Sus Road, Pashan, Pune, Maharashtra 411021, India.
  • Ella KM; Bharat Biotech International Limited, Genome Valley, Hyderabad, Telangana 500 078, India.
  • Panda S; Indian Council of Medical Research,V. Ramalingaswami Bhawan, P.O. Box No. 4911, Ansari Nagar, New Delhi 110029, India.
  • Bhargava B; Indian Council of Medical Research,V. Ramalingaswami Bhawan, P.O. Box No. 4911, Ansari Nagar, New Delhi 110029, India.
iScience ; 24(2): 102054, 2021 Feb 19.
Article en En | MEDLINE | ID: mdl-33521604
The availability of a safe and effective vaccine would be the eventual measure to deal with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) threat. Here, we have assessed the immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidates BBV152A, BBV152B, and BBV152C in Syrian hamsters. Three dose vaccination regimes with vaccine candidates induced significant titers of SARS-CoV-2-specific IgG and neutralizing antibodies. BBV152A and BBV152B vaccine candidates remarkably generated a quick and robust immune response. Post-SARS-CoV-2 infection, vaccinated hamsters did not show any histopathological changes in the lungs. The protection of the hamster was evident by the rapid clearance of the virus from lower respiratory tract, reduced virus load in upper respiratory tract, absence of lung pathology, and robust humoral immune response. These findings confirm the immunogenic potential of the vaccine candidates and further protection of hamsters challenged with SARS-CoV-2. Of the three candidates, BBV152A showed the better response.
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: IScience Año: 2021 Tipo del documento: Article País de afiliación: India

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: IScience Año: 2021 Tipo del documento: Article País de afiliación: India